Laboratorios Farmaceuticos Rovi, S.A. (LABFF) Acquisition Of An Injectable DrugTranscript

Marta Campos Martinez
Head of Investor Relations

Good afternoon, and thank you for joining us for this special conference call to discuss ROVI’s acquisition of an injectable drug product manufacturing site in Phoenix, Arizona, which we announced yesterday. Joining me on the call today is Juan Lopez-Belmonte, ROVI’s Chairman and Chief Executive Officer; and Javier Lopez-Belmonte, ROVI’s Deputy Chairman and Chief Financial Officer who will discuss the strategic rationale for the acquisition as well as the key terms of the transaction.

Javier is in Phoenix and he doesn’t have a good coverage. So we hope he can stay connected throughout the event. You will see a big presentation deck in the Investors section of our website. We’ll work through that deck on the call. And after that, we’ll open it up for Q&A. If you want to ask any questions during the presentation, please don’t hesitate to send them through the question bottom on the platform.

Before we get started, I note that some statements we may maybe consider forward-looking statements based on our current beliefs and expectations. Actual results could materially differ due to known and unknown risks, uncertainties and other factors, and we undertake no obligation to update or revise any of the statements.

So with that, I thank you for your presence here today. And we’ll now hand the presentation over to Juan Lopez-Belmonte, please go ahead.

Juan Encina
Chairman & CEO

Thank you, Marta. Good morning, and thank you for joining us today. This is truly an exciting day